title: Lipodermatosclerosis secondary to pemetrexed use.
authors.affiliation: *Harvard Medical School, Boston, MA; †Harvard Combined Dermatology Residency Program, Boston, MA; ‡Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA; and §Department of Dermatology, Massachusetts General Hospital, Boston, MA.
authors.forename: Marina
authors.initials: M
authors.lastname: Shuster
authors.forename: Keith
authors.initials: K
authors.lastname: Morley
authors.forename: Jennifer
authors.initials: J
authors.lastname: Logan
authors.forename: Lecia V
authors.initials: LV
authors.lastname: Sequist
authors.forename: Alice
authors.initials: A
authors.lastname: Shaw
authors.forename: Panos
authors.initials: P
authors.lastname: Fidias
authors.forename: Daniela
authors.initials: D
authors.lastname: Kroshinsky
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003872:Dermatitis / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000068437:Pemetrexed / Q000009:adverse effects*; D011379:Prognosis; D012594:Scleroderma, Localized / Q000139:chemically induced* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D000068437:Pemetrexed